Inari Medical, Inc. (NARI) Misses Q3 EPS by 19c, provides guidance

Go back to Inari Medical, Inc. (NARI) Misses Q3 EPS by 19c, provides guidance

Inari Medical Inc. (NARI) PT Raised to $50 at Truist Securities

October 29, 2024 5:57 AM EDT

Truist Securities analyst Richard Newitter raised the price target on Inari Medical Inc. (NASDAQ: NARI) to $50.00 (from $46.00) while maintaining a Hold rating.

The analyst comments "NARI's 3Q profit beat shld help the stock recover a bit (up +9% AMC) some of its recent pullback... More

BTIG Reiterates Buy Rating on Inari Medical Inc. (NARI)

October 29, 2024 5:47 AM EDT

BTIG analyst Marie Thibault reiterated a Buy rating and $86.00 price target on Inari Medical Inc. (NASDAQ: NARI).

The analyst comments "Inari Medical reported Q3 revenue of $153.4M (+21.4% y/y and +5% sequentially), above consensus of $150.7M. NARI had previously set a Q3 sales outlook that implied ~$150M this ~$3M beat vs our expectations was driven by U.S. VTE and International sales growth. The full-year revenue outlook was... More